Keenova presents new clinical analysis

Keenova Therapeutics plc has announced the presentation of a new clinical analysis related to hepatorenal syndrome-acute kidney injury (HRS-AKI) and its treatment, TERLIVAZ®. The presentation, delivered at the SHM Converge conference, likely highlights recent findings and advancements in understanding and managing this critical medical condition. Such analyses are crucial for informing clinical practice and potentially guiding future research and development efforts in the pharmaceutical sector, contributing to improved patient outcomes.